Use of APE1 / REF-1 inhibitors in combination therapeutics for the treatment of cancer

摘要

Depurinization Depyrimidine Site Endonuclease / A combination therapeutic agent comprising an APE1 / Ref-1 inhibitor specific for inhibiting the redox function of redox factor 1 (APE1 / Ref-1) is described herein Disclosed. This combination therapeutic agent can be used to treat various cancers and other angiogenesis-mediated diseases (eg, retinal disease, cardiovascular disease). [Selection diagram] Figure 1